Metabolic signature of extracellular vesicles depends on the cell culture conditions by Palviainen, Mari et al.
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=zjev20
Journal of Extracellular Vesicles
ISSN: (Print) 2001-3078 (Online) Journal homepage: https://www.tandfonline.com/loi/zjev20
Metabolic signature of extracellular vesicles
depends on the cell culture conditions
Mari Palviainen, Heikki Saari, Olli Kärkkäinen, Jenna Pekkinen, Seppo
Auriola, Marjo Yliperttula, Maija Puhka, Kati Hanhineva & Pia R.-M. Siljander
To cite this article: Mari Palviainen, Heikki Saari, Olli Kärkkäinen, Jenna Pekkinen, Seppo Auriola,
Marjo Yliperttula, Maija Puhka, Kati Hanhineva & Pia R.-M. Siljander (2019) Metabolic signature of
extracellular vesicles depends on the cell culture conditions, Journal of Extracellular Vesicles, 8:1,
1596669, DOI: 10.1080/20013078.2019.1596669
To link to this article:  https://doi.org/10.1080/20013078.2019.1596669
© 2019 The Author(s). Published by Informa
UK Limited, trading as Taylor & Francis
Group on behalf of The International Society
for Extracellular Vesicles.
View supplementary material 
Published online: 04 Apr 2019.




Metabolic signature of extracellular vesicles depends on the cell culture
conditions
Mari Palviainen a,b, Heikki Saari c, Olli Kärkkäinen d,e, Jenna Pekkinend,e, Seppo Auriolae,f, Marjo Yliperttulac,
Maija Puhkab,g, Kati Hanhinevad,e and Pia R.-M. Siljander a,b,c
aEV-group, Molecular and Integrative Biosciences Research Programme, Faculty of Biological and Environmental Sciences, University of
Helsinki, Helsinki, Finland; bEV-core, University of Helsinki, Helsinki, Finland; cDrug Research Program, Faculty of Pharmacy, Division of
Pharmaceutical Biosciences, University of Helsinki, Helsinki, Finland; dInstitute of Public Health and Clinical Nutrition, University of Eastern
Finland, Kuopio, Finland; eLC-MS Metabolomics Center, University of Eastern Finland, Kuopio, Finland; fSchool of Pharmacy, University of
Eastern Finland, Kuopio, Finland; gInstitute for Molecular Medicine Finland FIMM, University of Helsinki, Helsinki, Finland
ABSTRACT
One of the greatest bottlenecks in extracellular vesicle (EV) research is the production of sufficient
material in a consistent and effective way using in vitro cell models. Although the production of
EVs in bioreactors maximizes EV yield in comparison to conventional cell cultures, the impact of
their cell growth conditions on EVs has not yet been established. In this study, we grew two
prostate cancer cell lines, PC-3 and VCaP, in conventional cell culture dishes and in two-chamber
bioreactors to elucidate how the growth environment affects the EV characteristics. Specifically,
we wanted to investigate the growth condition-dependent differences by non-targeted metabo-
lite profiling using liquid chromatography–mass spectrometry (LC–MS) analysis. EVs were also
characterized by their morphology, size distribution, and EV protein marker expression, and the
EV yields were quantified by NTA. The use of bioreactor increased the EV yield >100 times
compared to the conventional cell culture system. Regarding morphology, size distribution and
surface markers, only minor differences were observed between the bioreactor-derived EVs (BR-
EVs) and the EVs obtained from cells grown in conventional cell cultures (C-EVs). In contrast,
metabolomic analysis revealed statistically significant differences in both polar and non-polar
metabolites when the BR-EVs were compared to the C-EVs. The results show that the growth
conditions markedly affected the EV metabolite profiles and that metabolomics was a sensitive
tool to study molecular differences of EVs. We conclude that the cell culture conditions of EV
production should be standardized and carefully detailed in publications and care should be
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Extracellular vesicles (EVs) are naturally occurring
intercellular communicasomes containing proteins
and nucleic acids, but also lipids and metabolites,
which mediate information between cells and tissues.
EV is the recommended umbrella term used to cover
the heterogeneity of vesicle populations formed
through different pathways [1], including plasma
membrane-derived microvesicles and multivesicular
body-derived exosomes. Additionally, changes in cell
status can produce various vesicle types such as apop-
totic bodies from apoptotic cells [1] or very large
“oncosomes” from cancerous cells that are also
regarded as EVs [2]. More, still unknown EV subtypes
are likely to exist which may differ in their
composition, ultrastructure, size, stimulus of produc-
tion, and/or originating pathway, as has been sug-
gested, for example regarding human ejaculate, where
several different classes of EVs were identified by their
morphology under cryo-transmission electron micro-
scopy [3]. The large variety of EV subtypes also high-
lights the multifaceted nature of EV-mediated
communication, as the EVs vary also in their molecular
content [1,4]. For example, EVs from cancerous pros-
tate cells significantly differ in their cargo from those
secreted by normal prostate epithelial cells [5], and
differences in content and function have also been
reported between EVs from prostate cancer cells of
varying metastatic potential [6,7]. However, properties
and functional effects have mostly been studied with
EVs obtained from in vitro cell cultures. As a matter of
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fact, 95% of the researchers authoring the new
MISEV2018 guidelines used in vitro cell models for
their EV studies [8], and until recently, not much
attention has been given to the effects of cell culture
conditions and growth environment in the EV studies
beyond the fetal bovine serum (FBS)-derived EVs.
Due to the origin-dependent composition and their
role as natural delivery agents, EVs offer significant
potential as diagnostic markers [9–11] and carriers of
therapeutic cargo [12–14]. The use of EVs for thera-
peutic applications, product development and research
(e.g. omics analyses) requires large amounts of EVs, for
which conventional cell culture systems are too ineffi-
cient, requiring active maintenance and processing of
large volumes of cell conditioned media. Bioreactors,
such as two-chamber or hollow-fibre bioreactors, in
which cells can be grown in high densities in a 3D-
like platform, present an attractive alternative for pro-
ducing more EVs [15,16]. However, it is currently
unknown how well the properties of the bioreactor-
derived EVs translate to the current knowledge of EVs,
mostly derived from EVs from cells grown in conven-
tional cell cultures.
In this study, we compared EVs (20K and 110K
subpopulations isolated by differential ultracentrifuga-
tion) from two commonly studied metastatic prostate
cancer cell lines, PC-3 and VCaP, which were cultured
either in conventional cell culture dishes (C-EVs) or
bioreactors (BR-EVs). To obtain the best snap-shot of
the versatility of the EV cargo, we focused on EV
metabolites by non-targeted metabolomics in addition
to the basic characterization of EVs.
Materials and methods
Cell culture
PC-3 and VCaP-prostate cancer cell lines were obtained
from the American Type Culture Collection (ATCC). All
reagents were purchased from Gibco, Life Technologies.
Both cell lines were tested negative for mycoplasma prior
to the study. Seeding density for both cell lines and culture
conditions was 4.5 × 106 cells/ml. Cells were grown at 37°C
and 5% of CO2 either in Celline 1000 AD model bioreac-
tors (Integra-Biosciences) according to the manufacturer’s
guidelines (http://wheaton.com/celline-ad-1000-flask
-3-cs-strl.html#support-tab, Wheaton Science Products)
or in T-175 flasks (Nunc). PC-3 cells (passage 16) were
grown in Dulbecco’s modified Eagle medium Nutrient
Mixture F-12 (DMEM/F12) and VCaP cells (passage 64)
in DMEM supplemented with 10% FBS and 1% of peni-
cillin/streptomycin (100 units/ml penicillin and 100 μg/ml
streptomycin). Cells grown in bioreactors were separated
from FBSwith a cellulose acetatemembrane of 10 kDa cut-
off. The FBS used in the T-175 flask cultures was centri-
fuged at 110,000 × g for 16 h to deplete extracellular
vesicles according to a previously published protocol [17].
EV isolation using differential ultracentrifugation
A flow chart of the isolation and analyses is presented
in Figure 1. EVs were isolated from the conditioned
media using differential ultracentrifugation as pre-
viously described [5] with slight modifications. Cell
culture media was collected consecutively every
3 days from conventionally cultured cells at 80% con-
Figure 1. Schematic overview of the workflow of the study.
Conditioned media from PC-3 and VCaP cells grown in cell
culture flasks or in bioreactors were harvested for extracellular
vesicles (EVs) by differential ultracentrifugation as 20K and
110K subpopulations. The isolated EVs were characterized by
nanoparticle tracking analysis (NTA), electron microscopy (EM)
and Western blotting, and the EV samples were submitted to
non-targeted metabolomics (liquid chromatography mass spec-
trometry, LC–MS). Respective media controls for metabolomic
profiling were incubated without cells at 37°C for 72 h and
processed by ultracentrifugation similarly as the 110K EV
samples. CM, conditioned media; RP, reverse phase; HILIC,
hydrophilic interaction liquid chromatography.
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fluence, when they were passaged. Culture medium was
collected once a week from bioreactor grown cells
(three consequent weeks) and replaced by fresh med-
ium, as instructed by the manufacturer. In brief, the
conditioned medium (180 ml from conventional cell
cultures and 10 ml from bioreactors) was first centri-
fuged to remove cell debris and apoptotic bodies at
2500 × g for 30 min. The supernatant was then cen-
trifuged at 20,000 gavg for 60 min for the 20K EV pellet,
and the final supernatant was ultracentrifuged at
110,000 gavg for 2 h in +4°C to obtain the 110K EV
pellet using Optima LE-80K ultracentrifuge with rotor
Ti 50.2, k-factor 143.3 (Beckman Coulter). For the
metabolomics analysis, media were incubated in the
absence of cells at 37°C, and after 3 days ultracentri-
fuged at 110,000 × g for 2 h, as a recommended control
[18]. The collected EVs were washed with 500 µl of PBS
and re-pelleted by ultracentrifugation at 100,000 × g,
+4°C for 2 h using Optima MAX-XP (Beckman
Coulter) ultracentrifuge with rotor TLA-55, k-factor
81.3 (Beckman Coulter). The 20K, 110K pellets and
media controls were then resuspended in 50 μl of
Dulbecco’s phosphate buffered saline (DPBS) (Gibco,
Life Technologies), and stored at −80°C for further
analysis. Data of this study have been submitted to
the EV-TRACK knowledgebase (EV-TRACK ID:
EV180029) [19].
Electron microscopy
Electron microscopy (EM) samples were prepared by
negative staining as described earlier [20]. Briefly, EVs
were loaded on 200 mesh grids, fixed with 2% PFA,
stained with 2% neutral uranyl acetate and embedded
in methyl cellulose uranyl acetate mixture. Stained
samples were viewed with Tecnai 12 (FEI Company)
at 80 kV.
Nanoparticle tracking analysis
Purified EV samples were analysed by nanoparticle
tracking analysis (NTA) using Nanosight model
LM14 (Nanosight) equipped with blue (404 nm,
70 mW) laser and SCMOS camera. The samples were
diluted in 0.1 µm filtered (Millex VV, Millipore) DPBS
to obtain 40–100 particles/view, and three 60 s videos
were recorded using camera level 14 with automatic
temperature setting of 22°C. The data were analysed
using NTA software 3.0 with the detection threshold 5
and screen gain at 10 to track as many particles as
possible with minimal background.
Western blotting
1.5E10 particles of C-EVs and 5E10 particles of BR-EVs
were prepared in Laemmli buffer under non-reducing
conditions, and separated by SDS-PAGE and transferred
onto PVDF membranes, and probed with antibodies
diluted 1:500 against human CD9 (HBD-CD9,
HansaBioMed Life Sciences Ltd), CD29 (#610,467, BD
Transduction Laboratories), CD81 (HBD-CD81-EM4,
HansaBioMed Life Sciences Ltd), TSG101 (BD
Biosciences), and 1:1000 Calnexin (Cell Signalling
Technology). Proteins of interest were detected with
1:3000 diluted HRP-conjugated IgG antibody (NA931
anti-mouse HRP, or NA934 anti-rabbit HRP, GE
Healthcare) and visualized with the Clarity ECL substrate
(BioRad).
Non-targeted LC–MS metabolite profile analysis
Metabolites were extracted from the EV samples in
triplicates by adding 400 μl acetonitrile to 100 μl each
sample and mixed thoroughly by vortexing. The sam-
ples were then centrifuged at 16,000 × g for 10 min,
and the supernatants were filtered with 0.2 μm
Acrodisc® Syringe filters with the PFTE membrane
(Pall Corporation, Ann Arbor, MI). For a quality con-
trol sample small aliquots from every individual sample
were pooled together. The extracted metabolites were
then further analysed using LC–MS instrumentation
consisting of a 1290 LC system, a Jetstream electro-
spray ionization (ESI) source, and a 6540 UHD accu-
rate-mass qTOF spectrometer (Agilent Technologies,
Wallbronn, Karlsruhe, Germany). The samples were
analysed using both reverse phase (RP, Zorbax Eclipse
XDB-C 18 column, Agilent Technologies, Palo Alto,
CA, USA) and hydrophilic interaction chromatography
(HILIC, Acquity UPLC BEH Column, Waters
Corporation, Milford, MA) to maximize the coverage.
For data acquisition, the mass range was set to 20–1600
amu with acquisition rate 1.67 spectra/s. For automatic
MS/MS spectrums from every precursor scan cycles,
four ions with the highest intensities were selected for
fragmentation. Collision energies used for fragmenta-
tion were 10, 20 and 40 eV. Data acquisition was
conducted with MassHunter Acquisition B.04.00
(Agilent Technologies).
Metabolomic data collection and statistical
analysis
The raw data were collected using the vendor’s soft-
ware MassHunter Qualitative Analysis B.05.00 (Agilent
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Technologies). For the statistical analysis, the raw
values of fragmentation were used, and normalization
to e.g. particle concentration was not performed due to
the differences in samples regarding EV numbers
obtained from the different cell lines under the differ-
ent growth environments. To reduce noise and remove
insignificant metabolite features, inclusion criteria for
the statistical analysis was defined so that the molecular
feature of interest was detected in minimum of 60% of
the samples in at least one replicate group. The data
processing and selection for the most discriminating
features between samples were performed in excel.
A paired t-test was performed for each feature (cut-
off p-value < 0.05). The remaining peaks were manu-
ally inspected in the LC–MS chromatograms and spec-
tra with the MassHunter software and ensured that the
molecular ion of certain compound was included into
the data-dependent MS/MS analysis, or targeted MS/
MS analysis was performed. The raw data were decon-
voluted, aligned and identified with MS DIAL [21], and
the identification of metabolites was verified by screen-
ing the mass and MS/MS fragmentation spectra in the
Human Metabolome Database HMDB [22] and LIPID
MAPS [23]. The fragmentation of the metabolites was
compared with that of the standards of the molecules
when available, or found in databases and verified with
earlier literature. To find the differences between the
C- and BR-EVs after controlling for the differences
between the media without cells, we excluded metabo-
lites with log2 fold change above +1 or below −1 in the
comparison between medium samples in the conven-
tional and bioreactor cultures. We then made compar-
isons for each cell line (PC-3 and VCaP) and for each
type of vesicle (20K and 110K) where log2 fold changes
above +1 and below −1 between the conventional and
bioreactor-derived EVs were considered biologically
significant.
Metabolic pathway analysis
Further pathway analysis was performed on the meta-
bolites with significant changes between respective
groups (p-value < 0.05 and fold change > 2). Pathway
information for each metabolite was extracted from
either Human Metabolome Database (HMDB) [22],
or Kyoto Encyclopedia of Genes and Genomes
(KEGG) [24]. More detailed analysis of identified
metabolites, and interesting pathways and networks
was performed by MetaboAnalyst [25]. Venn diagrams
were conducted using online tool (http://bioinfor
matics.psb.ugent.be/webtools/Venn/).
Results and discussion
Characterization of EVs derived from conventional
cell culture and bioreactors
In this study, we compared how cell culture conditions
influenced the properties of the 20K and 110K EV sub-
populations of EVs obtained by differential ultracentrifu-
gation from two prostate cancer cell lines (PC-3 and
VCaP) grown either in conventional culture dishes or in
bioreactors. The effect of the growth environment on the
EV-metabolome was studied in detail. When the concen-
trations of the C-EVs and BR-EVs were determined by
NTA, both the PC-3 and VCaP cell line-derived BR-20K
and BR-110K samples showed >100-fold increase in yield
(measured as a total of one isolation round), when com-
pared to the respective C-EVs (Figure 2(a)). The
improved yield is in line with the results from two pre-
vious studies, where bioreactors were shown to improve
the EV yield 10–12-fold (presented per volume) com-
pared to conventional cell culture seemingly without
major effects to the EV populations and properties
[16,26]. The main methodological differences of the stu-
dies are (i) the cell lines and media composition in the BR
cell compartment (containing FBS), (ii) the EV isolation
method, and (iii) the analyticalmethods, and these factors
may well explain the differences between studies. In our
study, the notably high yield suggests that bioreactors
provide a way to obtain large EV batches for analytical
and application purposes.
Next, the EVs were compared by size distribution,
morphology and protein marker expression. When the
size distributions of the EVs were measured by NTA
(Figure 2(b)), the VCaP C-EVs did not differ from the
BR-EVs, but the PC-3-derived BR-EVs were statisti-
cally significantly smaller than the C-EVs, when ana-
lysed by bins of size classes (Supplementary Table 1).
The shift in size ditribution measured with NTA was
verified by size measurement of individual PC-3 EVs
by manual inspection in EM (data not shown), suggest-
ing a possibility of a different EV population. By EM,
BR- and C-EVs had similar morphologies typically
attributed to EVs (Supplementary Figure 1A). Next,
we compared the EVs for the presence and absence of
typical protein markers by Western blotting. The 20K
and 110K EVs derived from both culture systems were
positive for the markers CD9, CD29, CD81, and
TSG101, and negative for calnexin, which was used as
a negative marker control (Supplementary Figure 1B,
1C). Regarding CD29, some differences between the
marker profiles were seen between the cell culture
environments, so that CD29 in the C-EVs was fairly
evenly present in the 20K and 110K samples, but in the
4 M. PALVIAINEN ET AL.
BR-EVs, CD29 was more prominent in the 20K sam-
ples. Regarding CD9 and TSG101, the marker levels
were fairly similar in the 20K and 110K samples irre-
spective of the cell culture conditions. Regarding CD81,
differences were more marked between the 20K and
110K EV subpopulations than between the cell lines or
the cell culture environments. In conclusion, the most
profound effect of the cell culture environment was on
the EV yield per isolation, whereas differences in size
distribution, morphology and protein marker expres-
sion varied depending on the cell type, EV subpopula-
tion or the culture condition.
Non-targeted LC-MS metabolite profile analysis of
EVs derived from cells grown in conventional cell
culture and bioreactors
Next, the EV samples were subjected to non-targeted
metabolomics to get a temporal snapshot of their mole-
cular content. From the LC–MS measurements of the
EVs, 6006 molecular features were extracted with the
RP column, and 851 with the HILIC column followed
by downstream statistical analysis. Of the total 6857
molecular features, 459 showed statistically significant
differences (407 in PC-3 and 409 in VCaP showing
considerable overlap) when pairwise comparisons
were performed between the C-EVs and BR-EVs. Of
these, 246 molecular features were identified by manual
inspection and 213 remained unidentified due to insuf-
ficient fragmentation data, due to the limited sample
amount. Principal component analysis (PCA) of all
samples and media controls revealed a clear separation
between the (i) culture conditions and (ii) media con-
trols indicating that divergence of cell metabolism is
reflected in the EVs depending on the growth environ-
ment (Figure 3(a)). When the overlapping and the
sample type-specific differential metabolites were com-
pared by Venn diagram (Figure 3(b)), one-third of
metabolites was found only in the C-EVs (32% i.e.
130 unique metabolites from the combined 20K and
110K C-EV samples of PC-3, and 29% i.e. 120 meta-
bolites from the combined 20K and 110K C-EV sam-
ples of VCaP). A closer inspection of the cell lines and
culture conditions revealed that the media controls of
the conventional cell culture systems contained >50%
Figure 2. (a) The average particle concentrations (particles/ml in log10 scale) of the 20K and 110K C-EVs and BR-EVs derived from
PC-3 and VCaP cell cultures measured with NTA (n = 3). (b) Combined NTA data of size distributions from three isolations of the 20K
and 110K C-EVs and BR-EVs derived from PC-3 and VCaP cell cultures. Mean sizes (nm ±SD) of the EVs are indicated in the figure.
Statistical analysis of the size distribution data is shown in Supplementary Table 1. Concentration of BR-EVs in primary axis and
C-EVs in secondary axis. C-20K is the 20,000 g EV pellet isolated from the conventional flasks, C-110K is the 110,000 g EV pellet from
the conventional flasks, BR-20K is the 20,000 g EV pellet from the bioreactor, BR-110K is the 110,000 g EV pellet from the bioreactor.
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more molecular features when compared to the bior-
eactor media controls (Figure 3(c)). This indicated that
the two-chamber bioreactor allowed only a part of the
medium compounds to pass the 10 kDa semi-
permeable membrane separating the chambers, which
can in part explain the differences in the metabolite
content between the bioreactor and the conventional
cell cultures. The metabolites that were different (log2
fold change above 1 or below −1) between media
samples from conventional and bioreactor systems are
shown in Supplementary File 1. In the C-EV samples,
most of the identified metabolites were detected in all
the sample types i.e. in the 20K and 110K C-EV sam-
ples (Figure 3(b)) and in the media control samples.
The amount of shared metabolites between the med-
ium and the combined C-EVs (20K and 110K) was
similar for both cell lines (PC3 83% and VCaP 70%).
In contrast in the BR-EVs, the percentages of the
shared metabolites with the respective medium control
were lower (40% and 30%, respectively). This could be
due to an increased consumption of metabolites during
the longer culture in bioreactor with increased cell
density or alternatively, the carry-over of metabolites
from media during isolation by differential ultracentri-
fugation despite the wash-step.
Further metabolite analysis revealed three different
clusters of metabolites. A heat map of K-means-
clustered metabolites shows prominent differences
between the C-EVs and BR-EVs from both cell lines
(Figure 4). Cluster 1 contains hydrophilic metabolites
that were downregulated in the BR-EVs compared to
C-EVs and media controls, suggesting that the meta-
bolic flux of these molecules was enhanced in the
bioreactor grown cells. Clusters 2 and 3 contain hydro-
phobic metabolites that were upregulated in the C-EVs,
but were downregulated in the BR-EVs as well as
media controls, suggesting differential packaging of
metabolites into EVs or metabolism of cells grown in
different culture systems.
The majority of the metabolites falling into clusters
2 and 3 belong to glycerophospholipids including plas-
malogens, phosphatidylcholines and sphingomyelins.
Glycerophospholipids are one of the main components
in biological membranes, including those of EVs [1,27].
BR-EVs contained significantly less phophatidylcho-
lines (PC) and phosphatidylethanolamines (PE), as
well as sphingomyelins (SM) in comparison to the
C-EVs (Figure 4). In general, SM has been found to
be an enriched lipid class in exosomes, whereas PC has
been considerd to be more prominent in microvesicles
[28,29]. de novo formation of PE and PC can occur via
Figure 3. (a) Principal component analysis (PCA) of the meta-
bolite molecular features according to the experimental con-
ditions analysed with LC-MS. For PCA, the metabolites of the
20K and 110K EVs of both cell culture conditions, as well as
all four media controls, were merged. Data points represent
the average values of three isolations. (b) VENN diagrams of
the identified metabolites from the conditioned media col-
lected from PC-3 and VCaP cell lines. (c) VENN diagrams of
the identified metabolites from the media controls. C-20K is
the 20,000 g EV pellet from the conventional flasks, C-110K
is the 110,000 g EV pellet isolated from the conventional
flasks, BR-20K is the 20,000 g EV pellet from bioreactor, BR-
110K is the 110,000 g EV pellet from bioreactor. BR-medium
and C-medium are the media controls from the bioreactors
and conventional cell culture flasks, respectively.
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several pathways (Figure 5), Kennedy pathway being
the most essential [30,31]. In cell cultures, FBS provides
a source for the external building blocks for PE and PC
synthesis. In the bioreactor used in this study, the cell
compartment medium was separated from the FBS
containing medium by a semipermeable membrane
which according to the manufacturer allows only nutri-
ents smaller than 10 kDa to pass through. Our results
imply that some of the building blocks for the lipid
synthesis may have had restricted passage through the
membrane, which then affected the glyserophospho-
and sphingolipid synthesis (Figure 5). Alternatively,
the metabolite differences in cluster 1 suggest that
cells grown in bioreactor may run out of nutrients
between sampling intervals altering the cell metabolism
and thereby possibly affecting the source and composi-
tion of the respective EVs.
Although our metabolomics approach offers
a glimpse of the lipid content of the analysed EVs, the
data cannot directly be compared with the earlier results
from specific EV lipidomic studies [4,29,32–39]. These
studies showed that the lipid composition of EVs dif-
fered from the parental cells, and that e.g. cholesterol,
SM, PC and PE lipid species were specifically enriched
in EVs, although also differences were found between
EV subtypes. In our study, the majority of the identified
lipids belonged to SM, PC and PE species (Figure 4),
which is in line with the results of previous lipidomic
studies. Furthermore, as seen in cluster 2 of Figure 4,
lysophosphatidylcholines (LPC) were enriched in the
C-EVs compared to the BR-EVs. Lipid compositions
have been shown to affect biological functions, homing
and uptake of EVs, and functional studies may generate
different results depending on how the parent cells were
grown. LPCs, which have a large headgroup to acyl
chain ratio, have a positive spontaneous curvature
favouring bending away from the headgroups [40].
Depending on the recipient cell or organ, LPC-
containing vesicles have been shown to facilitate various
reactions, for example, circulating IgM immunoglobu-
lins bound to LPC structures exposed on EV surface
(and apoptotic cells), and sentenced these EVs to be
cleared from the circulation [41]. LPC-rich EVs derived
from immunocompetent dendritic cells were shown to
have a different fate: they migrated to the lymph nodes
and participated in the dendritic cell maturation [42].
Finally, LPC in EVs may play a role in the vesicle
budding into MVB by triggering outer membrane leaflet
bending at the neck of the vesicle [43].
In addition, SM lipids were downregulated in the
BR-EVs compared to the C-EVs (Figures 4 & 5).
Exosomes have been shown to contain more SM lipids
compared to microvesicles or parental cells [28] – thus
our bioreactor cultures may have produced less exo-
somes. On the other hand, apoptotic cells produce
small vesicles that pellet in similar conditions, but
have dissimilar cargo compared to exosomes from
viable cells [44]. Therefore, the downregulation of
LPCs and SM lipids in the BR-EVs (Figure 4) suggests
that a poorer nutrient status (based on the media
results) could affect the condition of the cells, which
in turn may modulate the vesiculation profiles in these
cells. Altogether, the metabolomic characterization of
EVs showed that both prostate cancer cell lines grown
in bioreactor may have had reduced viability, despite
being harvested according to the manufacturer’s
instructions, but this needs to be confirmed with
further studies.
Finally, data in cluster 3 of Figure 4 showed down-
regulation of Plsm-PE in the BR-EVs implying changes
in the de novo lipid formation. Plasmalogens (Plsm) are
glycerophospholipids that contain an ether bond in the
sn-1-position to an alkenyl group and are enriched
Figure 4. Heat map showing the metabolites grouped by the
K-means clustering method constructed on the basis of impor-
tance for the 20K and 110K EVs of culture conditions and cell
lines. The standardized group mean values are shown. Values
were standardized by mean of all samples and standard devia-
tion: Standardized Value = [(Value) – Mean(of all samples)]/
Standard deviation(of all samples).
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with polyunsaturated fatty acids. More than 15% of
total phospholipids in mammalian cell membranes
are plasmalogens [45]. Previous studies have shown
enrichment of Plsm-PE in the EVs compared to the
parental cell (colorectal and prostate cancer cells)
[29,35]. Plasmalogens also affected the rigidity of the
cell membranes [46,47] stabilizing them and promoting
vesicle fusion in stop-flow kinetic assay [48,49]. Lipid
balance of the parent cells is likely to impact the lipid
composition of EVs and thereby the functions that
depend on it. More research is clearly needed to estab-
lish e.g. how the cell culture conditions modulate the
EV properties in functional assays, and this study alone
cautions against attributing functional properties solely
on e.g. cell type, if the cell culture conditions vary
between the EVs to be studied.
Although differential ultracentrifugation does not
enable isolation of pure EV subpopulations, it is gener-
ally accepted that it provides enriched pools of EV
subpopulations with different molecular content [5,50].
Comparison of the metabolites between the C-20K and
C-110K EV samples showed that the majority of the
metabolites were shared (Figure 3(b)). In contrast, the
BR-20K and BR-110K samples of both cell lines revealed
interesting differences. For example, serotonin was
detected only in the BR-110K EVs derived from both
PC-3 and VCaP cells and not in the BR-20K EVs
(Supplementary Table 2). However, in general, more
metabolites were detected in the BR-20K (368 in PC-
3/395 in VCaP) than in the BR-110K (348/315) samples.
After idenfitication, the 20K samples also had more
unique metabolites (18/45) than the 110K samples
(10/2) derived from PC-3/VCaP cells grown in the bior-
eactor, respectively. These included a large proportion of
the identified LPCs, and some PCs and SMs. This enrich-
ment could imply that the nutrient deprivation in the
bioreactor may affect more the metabolites carried in the
110K-EVs. Comparison of BR-EVs to C-EVs for each
Figure 5. Simplified diagram of the downregulated metabolic pathways of phosphatidylethanoloamine (PE), phosphatidylcholine
(PC) and sphingomyelin (SM) lipid synthesis in the EVs derived from the bioreactors (BR-EVs). Metabolites that were downregulated
in all the BR-EVs from both cell lines in comparison to the metabolites from all the C-EVs, are highlighted in red. The metabolites
belonging to the Kennedy pathway are underlined.
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cell line and sample type revealed prominent differences
in the abundance of metabolites (Supplementary Figure
2). BR-EVs had more downregulated (54 in PC-3 20K/54
in PC-3 110K/74 in VCaP 20K/91 in VCaP 110K) than
upregulated metabolites (2/4/9/1).
Pathway analysis
Finally, the metabolites of each EV sample were ana-
lysed by metabolite set enrichment analysis (MSEA) to
identify and interpret patterns of metabolite concentra-
tion changes in a biologically meaningful way [51].
Although the total number of identified metabolites
was lower in the BR-EVs, exactly the same metabolic
pathways were discovered when compared to those
identified by the C-EV -metabolites (data not shown).
Next, we wanted to identify the metabolic pathways the
differential metabolites from the 20 K and 110 K sam-
ples belonged to (present in C-EVs, but absent in BR-
EVs) (Figure 6). Data from both cell lines showed that
thiamine – and vitamin B6 – as well as several amino
acid metabolic routes were affected by the growth
environment resulting into nutrient-poorer EVs from
bioreactors. Amino acids transported by the exosomes
have been shown to affect the tricarboxylic acid cycle of
the recipient cancer cells and thereby improve the
nutrient status of the fast growing and proliferating
cells by providing material for biosynthesis [52]. In
our previous study [14], both 20K and 110K EVs
from conventionally cultured prostate cancer cells
enhanced the viability of the cells of the respective
Figure 6. Metabolic pathway analysis of the enrichment of the unique metabolites found in the C-EVs (20K and 110K) which were
absent in the BR-EVs. Summary plots of the Metabolite Set Enrichment Analyses (MSEA) of PC-3 C-20K versus BR-20K and C-110K
versus BR-110K, and of VCaP C-20K versus BR-20K and C-110K versus BR-110K. Metabolites are ranked according to the p-value.
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cell lines, supporting the concept that cancerous cells
utilize the EV cargo as building blocks for their growth.
Based on the results from this study, the means of
producing EVs and the cell culture conditions should be
carefully considered and reported, when EVs are studied
for biological knowledge or utilized for theranostic
applications. The effect of various parameters, e.g. cell
type, cell confluence and cellular stress in cell culture
conditions on EV preparations, has been previously
reviewed [53]. One factor for the observed differences
in the EV metabolomes in our study may be confluence,
as during C-EV production, confluence was maintained
below 80%, while in bioreactors, culture is continued
without passaging, and the platform has been shown to
double the cell numbers and enable spheroid-like devel-
opment [16], which may affect the metabolic activity of
the cells [54,55]. Furthermore, increasing harvesting
intervals with concomitant exchange of fresh medium
may stabilize culture conditions and increase yields of
more conventional cell culture -like EVs minimizing
apoptotic or stress conditions. However, for physiologi-
cally relevant EV production, 3D cell culture technolo-
gies e.g. with spheroids should ultimately be adopted. In
the future, the properties of EVs could be manipulated
by controlling the cell culture conditions in bioreactors
in a similar way that biosimilars are tailored [56,57].
Conclusions
So far, the majority of EVs for basic research, thera-
peutics, and drug delivery have been isolated from cell
culture conditioned media. For most of these applica-
tions, conventional cell culture in large flasks is too
inefficient and laborious to produce sufficient amounts
of EVs in an economical way. Bioreactors can improve
the EV yield to > 10-fold or more compared to stan-
dard cell culture systems suggesting that bioreactors
provide a way to obtain large EV batches for analytical
and application purposes. However, we also found cell
culture system-dependent differences in the resulting
EVs. A few differences were seen in the basic EV
properties, but the most striking variation was in the
EV metabolomes. Our results warrant further investi-
gation into how EV applicability could be customized
by culture conditions. For example, nutrient poor EVs,
such as those from bioreactors in this study, could in
the future be custom tailored as drug delivery vehicles
which would provide minimal external energy or struc-
tural building blocks to the cancer cells. The bioreactor
conditions regarding the medium composition and the
interval of culture maintenance could be optimized for
each purpose. Finally, our study shows that metabolo-
mics provides a temporally precise and detailed snap
shot of the molecular properties of EVs, and is a useful
tool for understanding EV-mediated molecular
mechanisms. Although the EV-metabolome is still lar-
gely unknown, it shows great promise to be mined for
information such as biomarkers of systematic diseases,
e.g. cancer, as already suggested by the few pioneering
studies [58–61].
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